9 p.m., July 27
Biotech Sequenom Stock Up 32% on Optimism for Down Syndrome Test
Shares of biotech Sequenom are up 31.57 percent this morning (10 a.m. Sept. 24) to $27.05, a six-year high, after the company reported additional positive results for a test for Down syndrome. Some say the test will be able to detect Down syndrome at week 10 in a pregnancy or even earlier. One analyst says that in five years, hormone screening and amniocentesis will no longer be the standard of care for prenatal Down syndrome testing. The company expects to launch the test in June of next year.